Herman Gist
Cardiovascular Disease · Washington, DCNPI 1275528234
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations.
Across 111 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$327
- Gilead$273
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$199
- Pfizer$168
- Johnson & Johnson$139
- Boston Scientific$115
- plus $819 from 14 others
What the payments were for
- Food & beverage$2,039100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $327 |
| Gilead | 23 | $273 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $199 |
| Pfizer | 8 | $168 |
| Johnson & Johnson | 6 | $139 |
| Boston Scientific | 6 | $115 |
| Amgen | 5 | $105 |
| AstraZeneca | 5 | $96 |
| Abbott | 4 | $86 |
| Medtronic(2 entities) | 3 | $85 |
| Novo Nordisk | 4 | $78 |
| Irhythm Technologies, Inc. | 1 | $75 |
| Boehringer Ingelheim | 2 | $61 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Actelion Pharmaceuticals US, Inc. | 1 | $40 |
| Atricure, Inc. | 1 | $26 |
| Cardiovascular Systems Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
How this compares
$2,039 in reported general payments places this provider in the 55th percentile of 105 cardiovascular disease providers in District of Columbia.
See all cardiovascular disease providers in District of Columbia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $11,455 |
| Hydralazine Hcl | 15 | $593 |
| Losartan Potassium | 30 | $381 |
| Bumetanide | 11 | $317 |
| Amlodipine Besylate | 41 | $243 |
| Furosemide | 15 | $123 |
| Metoprolol Succinate | 13 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $168 | $11,45512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 105 cardiovascular disease providers in District of Columbia.
Other cardiovascular disease in Washington
- Hayder HashimWashington$824K
- Joshua YamamotoWashington$376K
- Mardi Gomberg-MaitlandWashington$320K
- Jaffar KhanWashington$318K
- Isaac Opoku-AsareWashington$146K
- Judith HsiaWashington$65K
- Ana BaracWashington$34K
- Jonathan PlehnWashington$32K
- Andrew ChoiWashington$32K
- Felton AndersonWashington$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.